SAN DIEGO, Dec. 04, 2025 (GLOBE NEWSWIRE) -- ViroMissile, Inc., a cancer immunotherapy company pioneering the IDOV™ (Intravenously Deliverable Oncolytic…
NAMPT inhibitor RPT1G demonstrated favorable safety and significant target engagement in first-in-human study Company to present Trial in Progress design…
– Data demonstrate superior efficacy compared to ruxolitinib, an approved type I JAK2 inhibitor, including reductions in mutant allele burden and…
Cohort 1 data from multiple dose ReSPECT- Leptomeningeal Metastases (LM) trial showed no dosage limiting toxicity ReSPECT-Glioblastoma (GBM) trial of…
One complete response and three partial responses observed in heavily pretreated ICI-secondary refractory patients in high dose cohorts Deep and durable…
Not for distribution by US newswire or in United States TORONTO, Dec. 04, 2025 (GLOBE NEWSWIRE) -- VAXIL BIO LTD.…
OSLO, Norway and HOUSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Thor Medical ASA, a leading emerging supplier of alpha-emitters for…
LISLE, IL / ACCESS Newswire / December 3, 2025 / Duly Health and Care, through one of its medical groups,…
DANVILLE, Calif., Dec. 3, 2025 /PRNewswire/ -- Dicom Systems, a leader in enterprise imaging interoperability and workflow orchestration, has reached…
MENLO PARK, Calif. and CINCINNATI, Dec. 3, 2025 /PRNewswire/ -- MyOme, a leading clinical whole-genome testing and polygenic risk modelling…